Nothing new here I think. And nothing specific regarding progress monetising oncology assets:
"Bionomics has an ongoing process to monetise its oncology programs through divestment and/or out-licensing both BNC101 and BNC105 as the company completes its transition to a focused Central Nervous System (CNS) disorders company."
BNC 210 RESTORE results expected late this quarter. Very close now. Fingers crossed.
Ann: Appendix 4C - quarterly, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)